The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Treatment Resistant Depression
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study
Tracking Information
- NCT #
- NCT03775200
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon